Evidence map›Paper›PMID 36521233›Full record

ArticleACS applied materials & interfaces2022

Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.

Lorena Simón-Gracia, Pablo Scodeller, William S Fisher, Valeria Sidorenko, Victoria M Steffes, Kai K Ewert, Cyrus R Safinya, Tambet Teesalu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024
    Article
  4. Brain Targeting Nanomedicines: Pitfalls and Promise.International journal of nanomedicine · 2024
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lorena Simón-GraciaLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia.ORCID 0000-0003-1825-8723
Pablo ScodellerLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia.ORCID 0000-0003-0745-2467
William S FisherMaterials Department, Molecular, Cellular, and Developmental Biology Department, Physics Department, and Biomolecular Science and Engineering Program, University of California, Santa Barbara, California 93106, United States.ORCID 0000-0002-7493-1567
Valeria SidorenkoLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia.ORCID 0000-0001-9932-1258
Victoria M SteffesMaterials Department, Molecular, Cellular, and Developmental Biology Department, Physics Department, and Biomolecular Science and Engineering Program, University of California, Santa Barbara, California 93106, United States.ORCID 0000-0002-5665-1131
Kai K EwertMaterials Department, Molecular, Cellular, and Developmental Biology Department, Physics Department, and Biomolecular Science and Engineering Program, University of California, Santa Barbara, California 93106, United States.ORCID 0000-0002-4861-8278
Cyrus R SafinyaMaterials Department, Molecular, Cellular, and Developmental Biology Department, Physics Department, and Biomolecular Science and Engineering Program, University of California, Santa Barbara, California 93106, United States.ORCID 0000-0002-3295-7128
Tambet TeesaluLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia.

Funding

Functionalized Lipid Carriers for Nucleic-Acid and Drug TherapeuticsR01GM130769 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI SAFINYA, CYRUS R · 2018 to 2021
$1.4M
NIGMS NIH HHS R01 GM130769
6 · The paper itself

Abstract

Novel approaches are required to address the urgent need to develop lipid-based carriers of paclitaxel (PTX) and other hydrophobic drugs for cancer chemotherapy. Carriers based on cationic liposomes (CLs) with fluid (i.e., chain-melted) membranes (e.g., EndoTAG-1) have shown promise in preclinical and late-stage clinical studies. Recent work found that the addition of a cone-shaped poly(ethylene glycol)-lipid (PEG-lipid) to PTX-loaded CLs (CLs

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsAnimalsCaspase 3Cell Line, TumorDrug CarriersFemaleHumansLipidsLiposomesMicePaclitaxelPolyethylene GlycolsTissue DistributionAntineoplastic Agents, PhytogenicCaspase 3Drug CarriersLipidsLiposomesPaclitaxelPolyethylene Glycolscationic liposomechemotherapyfluid lipid disk bicellepaclitaxelPEGylationtriple-negative breast cancertumor penetration

Identifiers

PMID36521233
PMCPMC9879205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.